Oncolytic viruses driven by tumor-specific promoters

Jayson Hardcastle, Kazuhiko Kurozumi, E. Antonio Chiocca, Balveen Kaur

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumor-specific transcriptional events.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalCurrent Cancer Drug Targets
Volume7
Issue number2
DOIs
Publication statusPublished - Mar 2007
Externally publishedYes

Fingerprint

Oncolytic Viruses
Carcinogens
Neoplasms
Virulence
Viruses
Safety
Molecular Biology
Clinical Trials
Infection

Keywords

  • Adenovirus
  • Cancer
  • HSV-1
  • Oncolytic viruses
  • Promoter
  • Transcriptional regulation

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Cite this

Oncolytic viruses driven by tumor-specific promoters. / Hardcastle, Jayson; Kurozumi, Kazuhiko; Chiocca, E. Antonio; Kaur, Balveen.

In: Current Cancer Drug Targets, Vol. 7, No. 2, 03.2007, p. 181-189.

Research output: Contribution to journalArticle

Hardcastle, Jayson ; Kurozumi, Kazuhiko ; Chiocca, E. Antonio ; Kaur, Balveen. / Oncolytic viruses driven by tumor-specific promoters. In: Current Cancer Drug Targets. 2007 ; Vol. 7, No. 2. pp. 181-189.
@article{9374da39fa4844ec8fdc918456ee7471,
title = "Oncolytic viruses driven by tumor-specific promoters",
abstract = "Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumor-specific transcriptional events.",
keywords = "Adenovirus, Cancer, HSV-1, Oncolytic viruses, Promoter, Transcriptional regulation",
author = "Jayson Hardcastle and Kazuhiko Kurozumi and Chiocca, {E. Antonio} and Balveen Kaur",
year = "2007",
month = "3",
doi = "10.2174/156800907780058880",
language = "English",
volume = "7",
pages = "181--189",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Oncolytic viruses driven by tumor-specific promoters

AU - Hardcastle, Jayson

AU - Kurozumi, Kazuhiko

AU - Chiocca, E. Antonio

AU - Kaur, Balveen

PY - 2007/3

Y1 - 2007/3

N2 - Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumor-specific transcriptional events.

AB - Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumor-specific transcriptional events.

KW - Adenovirus

KW - Cancer

KW - HSV-1

KW - Oncolytic viruses

KW - Promoter

KW - Transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=33847378926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847378926&partnerID=8YFLogxK

U2 - 10.2174/156800907780058880

DO - 10.2174/156800907780058880

M3 - Article

VL - 7

SP - 181

EP - 189

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 2

ER -